Literature DB >> 9804256

Hydrosalpinx fluid does not adversely affect the normal development of human embryos and implantation in vitro.

A Strandell1, A Sjögren, U Bentin-Ley, J Thorburn, L Hamberger, M Brännström.   

Abstract

Several retrospectively designed studies have shown an association between the presence of hydrosalpinx and impaired implantation and pregnancy rates among in-vitro fertilization (IVF) patients. In the present study we have evaluated the influence of hydrosalpinx fluid on normal human embryo development and implantation. Surplus, donated frozen embryos (n = 183) from IVF patients were used to study the effects on blastocyst development of hydrosalpinx fluid at concentrations of 50 and 100% compared with controls in S2 medium. The fluids were analysed for concentrations of electrolytes, osmolarity, protein content, endotoxin levels, bacterial or fungal contamination, pH and haemoglobin content. There was no difference in blastocyst development in cultures under mineral oil when control cultures (15/42 = 36%) were compared with cultures in 50% hydrosalpinx fluid (32/96 = 33%). The only biochemical parameter which correlated with capacity for blastocyst development was pH in hydrosalpinx fluid/medium (50/50%) after equilibration in 5% CO2 in air. When embryos were cultured in 100% hydrosalpinx fluid the blastocyst development was 14% (5/36) in comparison to control 33% (3/9). The original experiment was repeated in an open culture system without the protection of mineral oil but still in the presence of 50% hydrosalpinx fluid. The rate of blastocyst development was within the same range in the open system. In three separate experiments, the capability of expanded blastocyst to implant on multilayer artificial endometrium was tested. In these experiments, 1/3, 4/5 and 9/9 blastocysts implanted. The present study demonstrates that hydrosalpinx fluid does not generally exert any major negative effects on in-vitro development of human embryos or on the implantation process in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804256     DOI: 10.1093/humrep/13.10.2921

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Effect of endometrial cavity fluid on clinical pregnancy rate in tubal embryo transfer (TET).

Authors:  Robert Kuo-Kuang Lee; San-Li Yu; Yu-Fen Chih; Yi-Chun Tsai; Ming-Huei Lin; Yuh-Ming Hwu; Wen-Yu Huang; Jin-Tsung Su
Journal:  J Assist Reprod Genet       Date:  2006-05       Impact factor: 3.412

2.  The presence of cytokines and growth factors in hydrosalpingeal fluid.

Authors:  Annika Strandell; Jane Thorburn; Ann Wallin
Journal:  J Assist Reprod Genet       Date:  2004-07       Impact factor: 3.412

Review 3.  The Role of Hox Genes in Female Reproductive Tract Development, Adult Function, and Fertility.

Authors:  Hongling Du; Hugh S Taylor
Journal:  Cold Spring Harb Perspect Med       Date:  2015-11-09       Impact factor: 6.915

4.  Hydrosalpinx functional surgery or salpingectomy? The importance of hydrosalpinx fluid in assisted reproductive technologies.

Authors:  Mandakini Parihar; Aparna Mirge; Reshma Hasabe
Journal:  J Gynecol Endosc Surg       Date:  2009-01

5.  Endometrial cavity fluid is associated with deleterious pregnancy outcomes in patients undergoing in vitro fertilization/intracytoplasmic sperm injection: a retrospective cohort study.

Authors:  Wen-Xiu Zhang; Lian-Bao Cao; Ying Zhao; Jing Li; Bo-Feng Li; Jia-Nan Lv; Lei Yan; Jin-Long Ma
Journal:  Ann Transl Med       Date:  2021-01

6.  Effect of Pertubation on Pregnancy Rates before Intrauterine Insemination Treatment in Patients with Unexplained Infertility.

Authors:  Funda Yildiz; Nuray Bozkurt; Ahmet Erdem; Mehmet Erdem; Mesut Oktem; Recep Onur Karabacak
Journal:  Int J Fertil Steril       Date:  2014-03-09

7.  Extended doxycycline treatment versus salpingectomy in the management of patients with hydrosalpinx undergoing IVF-ET.

Authors:  Usama M Fouda; Hesham S Elshaer; Mohamed A Youssef; Fatma F Darweesh
Journal:  J Ovarian Res       Date:  2020-06-12       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.